John Mendelsohn Net Worth

The estimated Net Worth of John Mendelsohn is at least $75.7 mil dollars as of 14 December 2012. John Mendelsohn owns over 5,000 units of Merrimack Pharmaceuticals Inc stock worth over $75,650 and over the last 12 years John sold MACK stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Mendelsohn MACK stock SEC Form 4 insiders trading

John has made over 1 trades of the Merrimack Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently John bought 5,000 units of MACK stock worth $33,150 on 14 December 2012.

The largest trade John's ever made was buying 5,000 units of Merrimack Pharmaceuticals Inc stock on 14 December 2012 worth over $33,150. On average, John trades about 556 units every 0 days since 2012. As of 14 December 2012 John still owns at least 5,000 units of Merrimack Pharmaceuticals Inc stock.

You can see the complete history of John Mendelsohn stock trades at the bottom of the page.

What's John Mendelsohn's mailing address?

John's mailing address filed with the SEC is C/O MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE, MA, 02139.

Insiders trading at Merrimack Pharmaceuticals Inc

Over the last 13 years, insiders at Merrimack Pharmaceuticals Inc have traded over $1,152,598 worth of Merrimack Pharmaceuticals Inc stock and bought 3,978,994 units worth $28,464,218 . The most active insiders traders include Eric Western Standard Llcwe..., Robert J. Mulroy y Gary L Crocker. On average, Merrimack Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $459,997. The most recent stock trade was executed by Eric Western Standard Llcwe... on 26 December 2023, trading 49,550 units of MACK stock currently worth $651,583.

What does Merrimack Pharmaceuticals Inc do?

merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.

Complete history of John Mendelsohn stock trades at Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals Inc executives and stock owners

Merrimack Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Ulrik Nielsen,
  Independent Director
• Gary Crocker,
  Chairman of the Board, President, Treasurer
• Dr. Ulrik B. Nielsen,
  Co-Founder & Independent Director
• Gary L. Crocker M.B.A., MBA,
  Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
• Tim Surgenor,
  IR Contact Officer
• Russell Ray,
  Independent Director
• Noah Levy,
  Independent Director
• Eric Andersen,
  Independent Director
• Timothy R. Surgenor,
  Sec.
• Dr. Daryl C. Drummond Ph.D.,
  Head of Research
• Dr. Fazal R. Khan Ph.D.,
  Sr. VP of Manufacturing
• Ellen K. Forest,
  Head of HR
• Geoffrey Grande C.F.A.,
  Sr. Director of Communications
• Dr. Anthony J. Sinskey Ph.D., Sc.D.,
  Co-Founder and Scientific Advisor
• Ana Radeljevic,
  
• Sergio L. Santillana,
  Chief Medical Officer
• John M. Dineen,
  Director
• Yasir B. Al Wakeel,
  CFO and Head of Corp Dev
• Jeffrey A Munsie,
  General Counsel
• James H. Quigley,
  Director
• John Mendelsohn,
  Director
• William A. Sullivan,
  CFO and Treasurer
• Edward J. Stewart,
  SVP & Pres, Healthcare Sol
• Peter N Laivins,
  Head of Development
• Michael E Porter,
  Director
• Richard Peters,
  President and CEO
• Robert J. Mulroy,
  President and CEO
• Birgit M. Schoeberl,
  Head of Discovery
• Vivian S Lee,
  Director
• William M. Mc Clements,
  Head of Corporate Operations
• George Demetri,
  Director
• Thomas E. Jr. Needham,
  Chief Business Officer
• Jean M. Franchi,
  Chief Financial Officer
• Capital Management, Llcjfl ...,
  
• Lp22 Nw Fund, Lp22 Nw Fund ...,
  
• Gordon J. Fehr,
  Director
• Anthony J Sinskey,
  Director
• James Van B. Dresser,
  Director
• Sarah E Nash,
  Director
• Fazal R. Khan,
  SVP of Manufacturing
• Robert C Gay,
  Director
• Walter M Phd Lovenberg,
  Director
• Clet M. Niyikiza,
  EVP of Development
• Jason Aryeh,
  10% owner